The glucagon-like peptide-1 analogues therapy in the non-diabetic patients
DOI:
https://doi.org/10.56782/pps.127Keywords:
GLP-1 agonists, diabetes, obesity, liraglutide, semaglutideAbstract
Glucagon like peptide-1 (GLP-1) receptor agonists are a group of hypoglycemic drugs that are used primarily to treat type 2 diabetes both as monotherapy and in combination with other antidiabetic drugs. In contrast to most hypoglycemic drugs, GLP-1 receptor agonists not only do not cause weight gain, but can even lead to weight reduction. This is why they are recently also increasingly used in the treatment of obesity in patients without type 2 diabetes. Current research indicate that liraglutide and semaglutide are effective and safe methods of treatment for overweight and obesity in patients without diabetes. GLP-1 receptor agonists’ mechanism of action is related to the incretin system. They lowers glucose concentrations by increasing insulin secretion and suppressing glucagon release. Moreover, they cause a retardation of gastric emptying and affect the central nervous system, resulting in a decrease in appetite and stimulation of satiety. In addition, a rising number of research studies show that GLP-1 receptor agonists may also have beneficial effects in the treatment of other conditions, such as nervous and cardiovascular diseases, metabolic diseases or endocrine disorders. Due to the new findings, even more research should be carried out to further investigate and describe the multidirectional effects of these drugs.
Downloads
References
Ratajczak, A., M. Szulińska, and P. Bogdański, Agoniści GLP-1 dla lekarzy praktyków. Forum Zaburzeń Metabolicznych, 2014. 5(4): p. 165-171. https://journals.viamedica.pl/forum_zaburzen_metabolicznych/article/view/40783
Strojek, K., Układ inkretynowy w cukrzycy typu 2: patofizjologia i możliwości terapii. Kreo 2011: p. 71−83.
Farilla, L., et al., Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. Endocrinology, 2003. 144(12): p. 5149-5158. https://academic.oup.com/endo/article/144/12/5149/2880380?login=false DOI: https://doi.org/10.1210/en.2003-0323
Tilinca, M.C., et al., A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review. Medicina (Kaunas), 2021. 57(7). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307742/ DOI: https://doi.org/10.3390/medicina57070669
Trujillo, J.M., W. Nuffer, and B.A. Smith, GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab, 2021. 12: p. 2042018821997320. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953228/ DOI: https://doi.org/10.1177/2042018821997320
Singh, S., et al., Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab, 2017. 19(2): p. 228-238. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299485/ DOI: https://doi.org/10.1111/dom.12805
Vilsbøll, T., et al., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj, 2012. 344: p. d7771. https://www.bmj.com/content/344/bmj.d7771 DOI: https://doi.org/10.1136/bmj.d7771
Garvey, W.T., et al., Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care, 2020. 43(5): p. 1085-1093. https://diabetesjournals.org/care/article/43/5/1085/35698/Efficacy-and-Safety-of-Liraglutide-3-0-mg-in DOI: https://doi.org/10.2337/dc19-1745
Marso, S.P., et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2016. 375(4): p. 311-22. https://www.nejm.org/doi/full/10.1056/nejmoa1603827 DOI: https://doi.org/10.1056/NEJMc1611289
Marso, S.P., et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2016. 375(19): p. 1834-1844. DOI: https://doi.org/10.1056/NEJMoa1607141
Gerstein, H.C., et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 2019. 394(10193): p. 121-130. https://www.sciencedirect.com/science/article/abs/pii/S0140673619311493
Kanie, T., et al., Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013650. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812344/ DOI: https://doi.org/10.1002/14651858.CD013650.pub2
Hasanzad, M., et al., A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. J Diabetes Metab Disord, 2020. 19(2): p. 1863-1872. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843728/ DOI: https://doi.org/10.1007/s40200-020-00619-9
International Diabetes Federation. IDF Diabetes Atlas—9th Edition. DiabetesAtlas.
Zheng, Y., S.H. Ley, and F.B. Hu, Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 2018. 14(2): p. 88-98. https://www.nature.com/articles/nrendo.2017.151 DOI: https://doi.org/10.1038/nrendo.2017.151
Apovian, C.M., J. Okemah, and P.M. O’Neil, Body Weight Considerations in the Management of Type 2 Diabetes. Advances in Therapy, 2019. 36(1): p. 44-58. https://link.springer.com/article/10.1007/s12325-018-0824-8 DOI: https://doi.org/10.1007/s12325-018-0824-8
Association, A.D., 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care, 2020. 44(Supplement_1): p. S111-S124. https://diabetesjournals.org/care/article/44/Supplement_1/S111/31020/9-Pharmacologic-Approaches-to-Glycemic-Treatment DOI: https://doi.org/10.2337/dc21-S009
Marre, M., et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med, 2009. 26(3): p. 268-78. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871176/ DOI: https://doi.org/10.1111/j.1464-5491.2009.02666.x
Russell-Jones, D.V., A.A.; Schmitz, O.; Sethi, B.K.; Lalic, N.; Anti´c, S.; Zdravkovic, M.; Ravn, G.M.; Simo, R. , On behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009. Diabetologia 2009. 52. https://link.springer.com/article/10.1007/s00125-009-1472-y DOI: https://doi.org/10.1007/s00125-009-1472-y
Alsugair, H.A., et al., Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. Healthcare (Basel), 2021. 9(9). https://www.mdpi.com/2227-9032/9/9/1125 DOI: https://doi.org/10.3390/healthcare9091125
Iepsen, E.W., S.S. Torekov, and J.J. Holst, Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther, 2015. 13(7): p. 753-67. https://www.tandfonline.com/doi/abs/10.1586/14779072.2015.1054810 DOI: https://doi.org/10.1586/14779072.2015.1054810
Chou, C.A. and S.F. Chuang, Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients. J Diabetes Investig, 2020. 11(6): p. 1524-1531. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610111/ DOI: https://doi.org/10.1111/jdi.13314
Lean, M.E., et al., Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 2018. 391(10120): p. 541-551. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33102-1/fulltext DOI: https://doi.org/10.1016/S0140-6736(17)33102-1
Lean, M.E.J., et al., Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol, 2019. 7(5): p. 344-355. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30068-3/fulltext
Abd El Aziz, M., et al., Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab, 2020. 22(4): p. 699-704. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.13924 DOI: https://doi.org/10.1111/dom.13924
Holst, J.J., Incretin hormones and the satiation signal. Int J Obes (Lond), 2013. 37(9): p. 1161-8. https://www.nature.com/articles/ijo2012208 DOI: https://doi.org/10.1038/ijo.2012.208
Haining Wang MD, Y.L.M., Qing Tian MD,Jin Yang MD,Ran Lu MD,Siyan Zhan PhD,Jari Haukka PhD,Tianpei Hong MD, Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018. 20. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.13177 DOI: https://doi.org/10.1111/dom.13177
Nauck, M., et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009. 32(1): p. 84-90. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/ DOI: https://doi.org/10.2337/dc08-1355
Sfairopoulos, D., et al., Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones, 2018. 17(3): p. 333-350. https://link.springer.com/article/10.1007/s42000-018-0038-0 DOI: https://doi.org/10.1007/s42000-018-0038-0
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017. 377(1): p. 13-27. https://www.nejm.org/doi/full/10.1056/nejmoa1614362 DOI: https://doi.org/10.1056/NEJMoa1614362
Bąk-Sosnowska M., B.M., et.all., Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa Leczenia Otyłości. . Med. Prakt. , 2022(wyd. specj.;): p. 1–87. https://ptlo.org.pl/aktualnosci/209-pdf__zalecenia_kliniczne_dotyczace_postepowania_u_chorych_na_otylosc_2022
Zhong, P., et al., Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine, 2022. 75(3): p. 718-724. https://link.springer.com/article/10.1007/s12020-021-02945-1 DOI: https://doi.org/10.1007/s12020-021-02945-1
Zhang, P., et al., The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci, 2019. 19(3): p. 2591-2599. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040262/ DOI: https://doi.org/10.4314/ahs.v19i3.35
Barboza, J.J., et al., Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med, 2022. 11(11). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181568/ DOI: https://doi.org/10.3390/jcm11112998
EMA. European public assessment report (EPAR) for Saxenda. 2015; Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda.
Rubino, D.M., et al., Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Jama, 2022. 327(2): p. 138-150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753508/ DOI: https://doi.org/10.1001/jama.2021.23619
O'Neil, P.M., et al., Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 2018. 392(10148): p. 637-649. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31773-2/fulltext DOI: https://doi.org/10.1016/S0140-6736(18)31773-2
Salcedo, I., et al., Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology, 2012. 166(5): p. 1586-1599. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419902/ DOI: https://doi.org/10.1111/j.1476-5381.2012.01971.x
Yildirim Simsir, I., U.E. Soyaltin, and S. Cetinkalp, Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease. Diabetes Metab Syndr, 2018. 12(3): p. 469-475. https://www.sciencedirect.com/science/article/abs/pii/S1871402117304782?via%3Dihub DOI: https://doi.org/10.1016/j.dsx.2018.03.002
Hölscher, C., Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology, 2018. 136(Pt B): p. 251-259. https://www.sciencedirect.com/science/article/abs/pii/S0028390818300406?via%3Dihub DOI: https://doi.org/10.1016/j.neuropharm.2018.01.040
Darsalia, V., et al., Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology, 2018. 136(Pt B): p. 280-286. https://pubmed.ncbi.nlm.nih.gov/28823610/ DOI: https://doi.org/10.1016/j.neuropharm.2017.08.022
Detka, J. and K. Głombik, Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacol Rep, 2021. 73(4): p. 1020-1032. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413152/ DOI: https://doi.org/10.1007/s43440-021-00274-8
Gong, N., et al., Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci, 2014. 34(15): p. 5322-34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608999/ DOI: https://doi.org/10.1523/JNEUROSCI.4703-13.2014
Sharma, A. and S. Verma, Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Can J Diabetes, 2020. 44(1): p. 93-102. https://www.canadianjournalofdiabetes.com/article/S1499-2671(19)30658-6/fulltext DOI: https://doi.org/10.1016/j.jcjd.2019.09.003
Cena, H., L. Chiovato, and R.E. Nappi, Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab, 2020. 105(8): p. e2695-709. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457958/ DOI: https://doi.org/10.1210/clinem/dgaa285
Newsome, P.N., et al., A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med, 2021. 384(12): p. 1113-1124. https://www.nejm.org/doi/full/10.1056/NEJMoa2028395 DOI: https://doi.org/10.1056/NEJMoa2028395
MZ: braki leku Ozempic spowodowane przepisywaniem pacjentom poza wskazaniami rejestracyjnymi. 2022; Available from: https://pulsmedycyny.pl/mz-braki-leku-ozempic-spowodowane-przepisywaniem-pacjentom-poza-wskazaniami-rejestracyjnymi-1165886.
Australian Government, T.D.o.H.a.A.C., Therapeutic Goods Administration. The current Ozempic (semaglutide) supply situation. 2022 4 November 2022]; Available from: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/ozempic-semaglutide-shortage.
FDA. Current and Resolved Drug Shortages and Discontinuations Reported to FDA, 2022; Available from: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
